Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
LEO Pharma A/S - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'LEO Pharma A/S - Product Pipeline Review - 2015', provides an overview of the LEO Pharma A/S's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of LEO Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of LEO Pharma A/S including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of LEO Pharma A/S's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the LEO Pharma A/S's pipeline products Reason to Buy - Evaluate LEO Pharma A/S's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of LEO Pharma A/S in its therapy areas of focus - Identify new drug targets and therapeutic classes in the LEO Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of LEO Pharma A/S and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of LEO Pharma A/S - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of LEO Pharma A/S and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 LEO Pharma A/S Snapshot 6 LEO Pharma A/S Overview 6 Key Information 6 Key Facts 6 LEO Pharma A/S - Research and Development Overview 7 Key Therapeutic Areas 7 LEO Pharma A/S - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 LEO Pharma A/S - Pipeline Products Glance 14 LEO Pharma A/S - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 LEO Pharma A/S - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 LEO Pharma A/S - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Discovery Products/Combination Treatment Modalities 18 LEO Pharma A/S - Drug Profiles 19 (calcipotriene + betamethasone dipropionate) 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 aprepitant 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 cromolyn sodium 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ingenol mebutate 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 LEO-43204 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 LP-0113 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 LEO-130852A 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LEO-32731 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 LEO-39652 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 VBY-891 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 LP-0067 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecules to Antagonize MCHR1 for Weight Loss 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules to Activate Protein Kinase C for Dermatology and Cancer 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LEO Pharma A/S - Pipeline Analysis 34 LEO Pharma A/S - Pipeline Products by Target 34 LEO Pharma A/S - Pipeline Products by Route of Administration 35 LEO Pharma A/S - Pipeline Products by Molecule Type 36 LEO Pharma A/S - Pipeline Products by Mechanism of Action 37 LEO Pharma A/S - Recent Pipeline Updates 38 LEO Pharma A/S - Dormant Projects 41 LEO Pharma A/S - Discontinued Pipeline Products 42 Discontinued Pipeline Product Profiles 42 (calcipotriene + hydrocortisone butyrate) 42 TD-1414 42 LEO Pharma A/S - Company Statement 43 LEO Pharma A/S - Locations And Subsidiaries 44 Head Office 44 Other Locations & Subsidiaries 44 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
LEO Pharma A/S, Key Information 6 LEO Pharma A/S, Key Facts 6 LEO Pharma A/S - Pipeline by Indication, 2015 8 LEO Pharma A/S - Pipeline by Stage of Development, 2015 9 LEO Pharma A/S - Monotherapy Products in Pipeline, 2015 10 LEO Pharma A/S - Combination Treatment Modalities in Pipeline, 2015 11 LEO Pharma A/S - Partnered Products in Pipeline, 2015 12 LEO Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2015 13 LEO Pharma A/S - Pre-Registration, 2015 14 LEO Pharma A/S - Phase II, 2015 15 LEO Pharma A/S - Phase I, 2015 16 LEO Pharma A/S - Preclinical, 2015 17 LEO Pharma A/S - Discovery, 2015 18 LEO Pharma A/S - Pipeline by Target, 2015 34 LEO Pharma A/S - Pipeline by Route of Administration, 2015 35 LEO Pharma A/S - Pipeline by Molecule Type, 2015 36 LEO Pharma A/S - Pipeline Products by Mechanism of Action, 2015 37 LEO Pharma A/S - Recent Pipeline Updates, 2015 38 LEO Pharma A/S - Dormant Developmental Projects,2015 41 LEO Pharma A/S - Discontinued Pipeline Products, 2015 42 LEO Pharma A/S, Other Locations 44 LEO Pharma A/S, Subsidiaries 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
